Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

Authors :: Plesner T
Arkenau HT
Gay F
Minnema MC
Boccadoro M
Moreau P
Cavenagh J
Perrot A
Laubach JP
Krejcik J
Ahmadi T
de Boer C
Chen D
Chiu C
Schecter JM
Richardson PG
Source :: British journal of haematology [Br J Haematol] 2019 Aug; Vol. 186 (3), pp. e35-e39. Date of Electronic Publication: 2019 Mar 31.
Publication Year :: 2019

Subjects :: Angiogenesis Inhibitors administration & dosage
Angiogenesis Inhibitors adverse effects
Antibodies, Monoclonal administration & dosage
Antibodies, Monoclonal adverse effects
Antineoplastic Combined Chemotherapy Protocols adverse effects
Dexamethasone administration & dosage
Dexamethasone adverse effects
Female
Humans
Lenalidomide administration & dosage
Lenalidomide adverse effects
Male
Neoplasm Recurrence, Local
Progression-Free Survival
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Multiple Myeloma drug therapy

Full Text Access

Tools